Natus Medical (NASDAQ:BABY) is a case in point as to why I'm always skeptical around growth stories built on rampant M&A activity, particularly when those growth stories are awarded the sort of multiples that go with the strongest organic growth names in the med-tech space. To that end, while Natus had a career-making run through the first decade of this century, the going has gotten a lot tougher post-2008, during which time Natus has lagged another famous (or infamous) growth-by-acquisition story Integra LifeSciences (NASDAQ:IART) and other less-than-stellar performers like Medtronic (NYSE:MDT).
Unfortunately, for Natus longs, I don't see this story getting dramatically better. While I do believe Natus will generate sufficient cash flow to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|